About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Long-Term, Open Label Atomoxetine Study | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 3NCT00190684

Long-Term, Open Label Atomoxetine Study

To learn about the safety and any side effects of atomoxetine when given to children and adolescents for about 5 years (long-term) and to learn whether atomoxetine can help children and adolescents wi...

Lead sponsor: Eli Lilly and Company•70 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Eli Lilly and Company

Age

6 - 18 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Must be at least 6 years old but less than 18 years old when enrolled in first atomoxetine study
•Must meet the study criteria for ADHD
•Must be willing to have blood drawn and to complete other test required for this study

Exclusion Criteria

•allergic to more than 1 kind of medicine or have had multiple bad reactions to any drug
•taking certain medicines that could interact with atomoxetine
•plan to move too far away from a doctor participating in this study in the next 5 years
•current or past history of any of the following: alcohol or drug abuse within the past 3 months, bipolar I or II disorder, high blood pressure, organic brain disease or seizures, psychosis, other disorders or conditions diagnosed by a doctor that might make you unsuitable to participate in this study

Related studies

Characterization of Social Cognition Profiles in Children and Adolescents With Neurodevelopmental Disorders: a Clinical Study Using a Multidimensional Battery

NCT07439276 · Neurodevelopmental Disorders, Autism Spectrum Disorder, and more

Developing Brain, Impulsivity and Compulsivity

NCT04631042 · Typical Development, Obsessive Compulsive Disorder, and more

Examination of the Dynamic Relationships of Sleep, Physical Activity, and Circadian Rhythmicity With Neurobehavioral Heterogeneity in ADHD

NCT06810180 · Attention Deficit Hyperactivity Disorder (ADHD), Sleep, and more

L-theanine and Paraxanthine for Cognitive Improvement in Adults With ADHD and ASD

NCT07189442 · Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD)

ADHD PreSMA Response Inhibition Therapy

NCT06325813 · Attention Deficit Hyperactivity Disorder

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 17, 2011Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE3

Enrollment1,553

Start dateAug 2000

Last updatedJan 17, 2011

Condition

Attention Deficit Hyperactivity Disorder

Locations shown

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Birmingham, Alabama

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Phoenix, Arizona

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

El Centro, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 17, 2011Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions